News | April 23, 2024
AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis
Open a printable version of this pageEmail the URL of this page to a friend
Open a printable version of this pageEmail the URL of this page to a friend
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Comprehensive clinical development programs being initiated for each investigational candidate
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
Demonstrate significant bleed reduction in hemophilia A and B
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Subscribe To Our Newsletter & Stay Updated
